EyePoint reported Q4 FY2025 total net revenue of USD 0.6 million (down 94.6%), including net product revenue of USD 0.3 million (down 61.4%) and license and royalty revenue of USD 0.3 million (down 97.2%), with the decline in license and royalties primarily driven by the recognition of remaining deferred revenue related to its 2023 agreement for the license of YUTIQ product rights. Q4 operating expenses were USD 71.0 million (up 25.0%), and net loss was USD 67.6 million, or USD (0.81) per share. For FY2025, EyePoint posted total net revenue of USD 31.4 million (down 27.5%), with net product revenue of USD 1.6 million (down 49.6%) and license and royalty revenue of USD 29.8 million (down 25.7%). FY operating expenses were USD 274.8 million (up 45.3%), and net loss was USD 232.0 million, or USD (3.17) per share. Cash, cash equivalents and investments were USD 306 million at December 31, 2025, and the company said this is expected to fund operations into Q4 2027. On the business side, EyePoint said both Phase 3 wet AMD trials for DURAVYU (LUGANO and LUCIA; over 900 patients) remain on track, with LUGANO topline data anticipated in mid-2026 and LUCIA shortly after; the program’s DSMC recommended continuation as planned with no protocol modifications. In DME, the first patient has been dosed in both Phase 3 COMO and CAPRI trials, with topline data expected in H2 2027. Corporate updates included the appointment of Michael Campbell as chief commercial officer, issuance of a U.S. patent expected to extend U.S. patent coverage for the DURAVYU insert formulation into 2043, completion of registration batch manufacturing for the planned wet AMD NDA CMC section, and an underwritten public offering completed in October 2025 with gross proceeds of USD 172.5 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EyePoint Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603040700PRIMZONEFULLFEED9665373) on March 04, 2026, and is solely responsible for the information contained therein.